Navigation Links
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
Date:7/20/2009

a sugar pill included dizziness, flu-like symptoms, diarrhea, cough, and tiredness. Other less common reactions to TEKTURNA and TEKTURNA HCT include skin rash and, additionally with TEKTURNA, cough.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "may," "will," "risk," "estimated," "committed," "potential," or similar expressions, or by express or implied discussions regarding potential future indications or labeling for Tekturna or Tekturna HCT, or regarding potential future revenues from Tekturna or Tekturna HCT. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Tekturna or Tekturna HCT will be approved for any additional indications or labeling. Nor can there be any guarantee that Tekturna or Tekturna HCT will achieve any particular levels of revenue in the future. In particular, management's expectations regarding Tekturna and Tekturna HCT could be affected by, among other things, unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; unexpected regulatory actions or delays or government regulation generally; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015  Hologic, Inc. (NASDAQ: HOLX ) ... new, five-year secured credit agreement consisting of a $1.5 ... credit facility. Hologic has borrowed $0.175 billion ... and the Term Loan to pay off the Company,s ... principal amount outstanding of $1.69 billion as of March ...
(Date:5/29/2015)... 2015  Excite Medical was established by its President, ... Excite Medical, under the leadership of Mr. Musallam ... a solid track record of providing unparalleled service and ... base.  Photo - http://photos.prnewswire.com/prnh/20150529/219412 ... been possible, in large part, due to Mr. ...
(Date:5/29/2015)... DUBLIN , May 28, 2015 Research ... of the "North America MRI Market - Growth, ... their offering. The North American MRI systems ... billion in 2014 to $1.58 billion by 2020 with ... systems are of three types namely, the open system, ...
Breaking Medicine Technology:Hologic Enters into Five-Year Secured Credit Agreement 2Hologic Enters into Five-Year Secured Credit Agreement 3North America MRI Market - Growth, Trends And Forecasts 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2
... LLC, a global leader in,non invasive high intensity ... of the Sonablate(R) International HIFU Registry,(SIHR), along with ... Takai,Hospital Supply Co., Ltd., (THS). The SIHR is ... about prostate cancer treatment using HIFU.,It was established ...
... candidates to ... obesity patients, SAN DIEGO, July 9 Orexigen(R) Therapeutics,Inc. ... randomizing patients,in ZB-202, a second Phase IIb clinical trial for ... trial is designed,to build on highly encouraging safety and efficacy ...
Cached Medicine Technology:Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments 2Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments 3Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule 2Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule 3Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule 4
(Date:5/30/2015)... The results of a 40+ year ... high potential to cause mesothelioma, regardless of the volume ... on the Surviving Mesothelioma website. , The study ... Lodz, Poland found that, among the 138 cases of ... 2012, all of them happened at plants that had, ...
(Date:5/30/2015)... CA (PRWEB) May 30, 2015 ProIntro Magnify ... unique designs and animations. Instantly add an elegant opening title ... choosing from a range of clean design layouts. ProIntro Magnify ... ProIntro Magnify is extremely easy to use. Simply drag a ... using the on-screen-controls and parameters in the Inspector window then ...
(Date:5/30/2015)... At 73 years old, Lynn Kendall ... which she attributes to a lifetime of being health-conscious. She ... the release of her new book titled “ Cook for ... for Health and Longevity” features a collection of recipes and ... food . It is designed to encourage a lifestyle of ...
(Date:5/30/2015)... May 30, 2015 San Luis ... she is offering a free analysis and consultation for ... coincides with Disability Awareness Month, which was created by ... across the United States such as Polk recognize the ... awareness about the possibility of disability, as well as ...
(Date:5/30/2015)... “ Milli the Snail ” was featured on ... look at the latest and coolest applications on the market ... AppWatch and technology expert, conducted the app review and shared ... and educates children. , Interactive mobile games for children have ... and games they are playing are doing much for their ...
Breaking Medicine News(10 mins):Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Announcing the release of ProIntro Magnify from Pixel Film Studios. 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 2Health News:Lynn Kendall Shows How to ‘Cook for Health and Longevity’ 3Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2Health News:An Aesthetic Game that Engages and Educates Children was Featured on NewsWatch Television 2
... University School of Medicine will add several new pediatric clinical rotations ... , ... North Brunswick, NJ (PRWEB) February 11, 2009-- ... will add several new pediatric clinical rotations to its growing network ...
... DaVita Inc.,(NYSE: DVA ) today announced results for ... the three months ended December 31, 2008 was $98.4,million, or ... per share,for the same period of 2007. , ... Net income for the year ended December 31, ...
... today reported significantly higher sales and earnings for both its fiscal third quarter and ... , Third quarter revenue increases 16% ... , Third quarter diluted EPS increases ... quarter of fiscal 2009, net sales increased 16 percent to $5,337,000 from $4,614,000 in ...
... First-Time AttendeesSTOWE, Vt., Feb. 10 The 9th Annual ... Learning for Survivors of All Cancers, and Those Who Love ... Stowe, Vermont, opens registration on February 24th, 2009.The Stowe ... has become one of the most inspiring, educational and unprecedented ...
... 10 Allscripts-Misys Healthcare,Solutions, Inc. ("Allscripts") announced today that ... under which Allscripts may purchase up to,$150 million of ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ... pursuant to Rule 10b5-1 or 10b-18 of the,Securities Exchange ...
... brain, researchers say , , TUESDAY, Feb. 10 (HealthDay News) ... don,t even bother to use them because they,re difficult ... nerves are allowing the brain to communicate directly with ... a banana and fold laundry. , "In the simplest ...
Cached Medicine News:Health News:Ross University School of Medicine Expands Clinical Rotations at Miami Children's Hospital 2Health News:DaVita 4th Quarter 2008 Results 2Health News:DaVita 4th Quarter 2008 Results 3Health News:DaVita 4th Quarter 2008 Results 4Health News:DaVita 4th Quarter 2008 Results 5Health News:DaVita 4th Quarter 2008 Results 6Health News:DaVita 4th Quarter 2008 Results 7Health News:DaVita 4th Quarter 2008 Results 8Health News:DaVita 4th Quarter 2008 Results 9Health News:DaVita 4th Quarter 2008 Results 10Health News:DaVita 4th Quarter 2008 Results 11Health News:DaVita 4th Quarter 2008 Results 12Health News:DaVita 4th Quarter 2008 Results 13Health News:DaVita 4th Quarter 2008 Results 14Health News:DaVita 4th Quarter 2008 Results 15Health News:DaVita 4th Quarter 2008 Results 16Health News:DaVita 4th Quarter 2008 Results 17Health News:DaVita 4th Quarter 2008 Results 18Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 2Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 3Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 4Health News:9th Annual Stowe Weekend of Hope Registration Opens February 24 2Health News:Allscripts Announces $150 Million Stock Repurchase Program and Increase in Credit Facility Commitments 2Health News:Allscripts Announces $150 Million Stock Repurchase Program and Increase in Credit Facility Commitments 3Health News:Allscripts Announces $150 Million Stock Repurchase Program and Increase in Credit Facility Commitments 4Health News:New Technology May Boost Artificial Arms 2
... fingertip ratchet disengagement allowing smooth, ratchet-free grasping. ... state-of-the-art quality in an instrument of extremely ... Low profile cutting tips allow access to ... instruments are available in just about every ...
... design provides fingertip ratchet disengagement allowing smooth, ... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ...
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... A broad selection of procedurally ... capability and allow easy access to ... a variety of approaches.,Loop Handled Graspers ... that holds tissue firmly without tearing ...
Medicine Products: